MENLO PARK, Calif., June 4, 2012 - Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, President and Chief Executive Officer, will present an overview of the company at 1:00 p.m. ET on Wednesday, June 6, at the Jefferies 2012 Global Healthcare Conference in New York City.

A live webcast of the audio and slide presentation will be available at http://wsw.com/webcast/jeff68/gern/. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.

About Geron

Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development, imetelstat and GRN1005. Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials: metastatic breast cancer, advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma. GRN1005 is a peptide-drug conjugate that is designed to transport a proven anti-cancer drug, paclitaxel, across the blood-brain barrier by targeting low-density lipoprotein receptor-related proteins (LRPs), specifically LRP-1. GRN1005 is being evaluated in two Phase 2 clinical trials: brain metastases arising from breast cancer and brain metastases arising from non-small cell lung cancer. For more information about Geron, visit www.geron.com.

CONTACT:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com

###